Previous Close | 23.67 |
Open | 23.87 |
Bid | 23.58 x 100 |
Ask | 23.66 x 100 |
Day's Range | 23.31 - 24.24 |
52 Week Range | 14.89 - 32.53 |
Volume | |
Avg. Volume | 717,617 |
Market Cap | 2.139B |
Beta (5Y Monthly) | 1.06 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.92 |
Earnings Date | May 02, 2024 - May 06, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 50.33 |
Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. The fund advanced 8.92% (Institutional Shares) in the quarter compared to an 8.52% gain for the Russell 3000 Health Care Index (benchmark) and a 10.56% increase for the S&P […]
The EMA accepts Rocket's (RCKT) regulatory submission seeking approval for RP-L102, a gene therapy for a rare genetic disorder called fanconi anemia that affects the bone marrow.
CRANBURY, N.J., April 02, 2024--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the European Medicines Agency (EMA) accepted the Marketing Authorization Application (MAA) for RP-L102, its lentiviral (LV) vector-based investigational gene therapy for Fanconi Anemia (FA), complementation group A, a rare genetic disorder caused by muta